ACM
RYTM icon

Altium Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Altium Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-57,271
Closed -$2.48M – 80
2024
Q1 		$2.48M Buy
57,271
+50,786
+783% +$2.22M 0.98% 31
2023
Q4 		$298K Buy
+6,485
New +$205K 0.2% 38
2023
Q1 		– Sell
-170,000
Closed -$4.95M – 105
2022
Q4 		$4.95M Hold
170,000
– – 2.52% 11
2022
Q3 		$4.17M Buy
+170,000
New +$3.16M 1.53% 18
2021
Q3 		– Sell
-104,840
Closed -$2.05M – 151
2021
Q2 		$2.05M Sell
104,840
-118,160
-53% -$2.45M 0.48% 81
2021
Q1 		$4.74M Buy
+223,000
New +$6.47M 1.32% 25

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Altium Capital Management's RYTM Position: Q2 2024 in Review

Altium Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2024, closing a stake of 57,271 shares — an estimated $2.48M sold.

Altium Capital Management first reported a position in RYTM in Q1 2021 and held it in 6 quarters. The position peaked at $4.95M in Q4 2022. 165 funds tracked by Wall St. Rank hold RYTM as of Q2 2024.

  • Altium Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Altium Capital Management sold 57,271 Rhythm Pharmaceuticals shares in Q2 2024, an estimated $2.48M.
  • Altium Capital Management first reported a position in Rhythm Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • Altium Capital Management's Rhythm Pharmaceuticals position peaked at $4.95M in Q4 2022.
  • 165 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2024.

Based on Altium Capital Management's 13F filing for Q2 2024, filed 15 Aug 2024.